ADAMTS7 Enhances Gastric Cancer Growth and Metastasis by Triggering the NF-κB Signaling Pathway

Shun Chen, Jiancheng He, Hanxu Gao, Xian Gao, Lingchen Dai, Junjie Chen, Zhenyu ShaJournal of Cancer 2024 · DOI

TL;DR

This study identifies ADAMTS7 as a key driver of gastric cancer (GC) progression, demonstrating its overexpression in GC tissues correlates with poor patient outcomes. By inhibiting ADAMTS7, researchers significantly reduced tumor growth and metastasis in preclinical models, suggesting ADAMTS7 is a promising therapeutic target and prognostic biomarker for GC.

What Problem Does This Paper Address?

Gastric cancer (GC) remains a significant global health challenge, characterized by high aggressiveness and mortality. Despite advancements in diagnostics and therapeutics, its prevention and treatment are complex due to multifactorial influences. While the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family of enzymes is known to play roles in tissue remodeling and cancer, the specific functions of many ADAMTS members, including ADAMTS7, in GC remain poorly understood. This paper aims to elucidate the role of ADAMTS7 in GC development and identify its underlying molecular mechanisms to uncover potential therapeutic strategies.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics Analysis: They screened public databases (TCGA, GEO) to identify differentially expressed ADAMTS family genes in GC and analyzed the prognostic significance of ADAMTS7 using Kaplan-Meier curves and Cox regression.
  • In Vitro Studies:
    • Cell Culture: Various GC cell lines (MKN-45, AGS, HGC27, SGC-7901, BGC-823) and a normal gastric epithelial cell line (GES-1) were used.
  • Gene Silencing: ADAMTS7 expression was reduced using shRNA (short hairpin RNA) delivered via lentiviral vectors. Transfection efficiency was confirmed by qRT-PCR and Western blot.
  • Functional Assays: * Cell Viability: CCK-8 assays were used to assess cell proliferation.
  • Colony Formation Assay: Assessed the ability of cells to form colonies, indicating long-term proliferation.
  • EDU Assay: Measured DNA synthesis to evaluate cell proliferation.
  • Transwell and Wound Healing Assays: Evaluated cell migration and invasion capabilities.
  • Western Blotting: Analyzed protein expression levels of key signaling molecules, including ADAMTS7, NF-κB pathway components (p-IKKβ, p-IκBα, p65), and loading controls (GAPDH, β-actin, Lamin B1).
  • Immunofluorescence (IF) Assay: Visualized the localization of NF-κB (p65) within cells.
  • In Vivo Studies:
    • Xenograft Tumor Models: Subcutaneous injection of GC cells into nude mice to assess tumor growth.
  • Peritoneal Metastasis Model: Intraperitoneal injection of GC cells to evaluate metastatic potential.
  • Immunohistochemistry (IHC): Stained tumor tissues to assess the expression of ADAMTS7, proliferation marker Ki67, and NF-κB p65.

Datasets

  • TCGA Database: The Cancer Genome Atlas, a comprehensive resource for cancer genomics.
  • GEO Microarrays: Publicly available gene expression datasets from the Gene Expression Omnibus (GSE65801, GSE51575, GSE33335, GSE30727).
  • Human GC Tissues: 120 pairs of GC tissues and their corresponding normal tissues collected from the Affiliated Hospital of Nantong University (2014-2016), with an additional 20 pairs for qRT-PCR.

Key Insights and Ideas

  • ADAMTS7 as a GC Driver: The study strongly implicates ADAMTS7 not just as a marker but as an active contributor to GC aggressiveness, driving proliferation, migration, and invasion.
  • NF-κB Pathway as a Key Mediator: The research uncovers a critical mechanistic link: ADAMTS7 appears to activate the NF-κB signaling pathway, which in turn promotes tumor progression. This provides a concrete molecular explanation for ADAMTS7's oncogenic role.
  • Therapeutic and Prognostic Potential: The findings position ADAMTS7 as a dual-purpose molecule – a potential target for novel therapies aimed at inhibiting its activity and a valuable biomarker for predicting patient prognosis.
  • Independent Risk Factor: ADAMTS7's association with poor outcomes, particularly tumor invasion (T-stage), appears to be independent of other common clinical and demographic factors, strengthening its significance as a specific GC marker.

Key Results

  • Overexpression in GC: ADAMTS7 mRNA and protein levels were significantly elevated in GC tissues compared to normal tissues.
  • Correlation with Poor Prognosis: High ADAMTS7 expression was significantly correlated with reduced overall survival and heightened metastatic potential in GC patients.
  • Inhibition of Malignancy: Silencing ADAMTS7 expression in GC cell lines significantly inhibited their proliferation, migration, and invasion.
  • Inhibition of Tumor Growth and Metastasis: In vivo studies showed that reducing ADAMTS7 levels significantly suppressed tumor growth and reduced the number of metastatic nodules in nude mice.
  • NF-κB Pathway Activation: ADAMTS7 knockdown led to decreased phosphorylation of IκBα and IKKβ, and reduced nuclear translocation of p65, indicating suppression of the NF-κB pathway. Conversely, activating the NF-κB pathway with an agonist reversed the inhibitory effects of ADAMTS7 knockdown.

Limitations and Future Work

  • Mechanism of ADAMTS7 Action: While the NF-κB pathway is identified as a key downstream target, the precise upstream mechanisms by which ADAMTS7 activates this pathway are not fully detailed.
  • Therapeutic Efficacy in Humans: The study's findings are based on in vitro and in vivo preclinical models. Further research is needed to validate these findings in human clinical trials and to develop specific ADAMTS7 inhibitors.
  • Broader ADAMTS Family Roles: While this study focuses on ADAMTS7, the paper acknowledges that other ADAMTS family members have diverse roles in GC, some as tumor suppressors and others as oncogenes. Further investigation into these complex interactions could provide a more comprehensive understanding of GC pathogenesis.
  • Future Directions: The authors suggest that ADAMTS7 is a promising therapeutic target and prognostic biomarker, opening avenues for developing targeted therapies to inhibit ADAMTS7 activity, potentially improving treatment outcomes and survival rates for GC patients.

Summary updated

Abstract

The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family of metalloproteinases plays a vital role in various biological and pathological processes, including tissue remodeling, angiogenesis, and cancer progression. Among the 19 ADAMTS family members, our research focused on ADAMTS7, which exhibited significant overexpression in gastric cancer (GC). This overexpression was strongly correlated with poor clinical outcomes, including reduced overall survival and heightened metastatic potential. To investigate the role of ADAMTS7 in GC, we employed an integrated approach encompassing bioinformatics analysis, Western blotting, immunofluorescence, as well as <i>in vitro</i> and <i>in vivo</i> functional analyses. Our results showed that silencing ADAMTS7 expression significantly inhibited the proliferation, migration, and invasion of GC cells, and furthermore, silencing ADAMTS7 significantly inhibited the growth and metastasis of tumour cells <i>in vivo</i> in nude mice, highlighting its critical role in driving the malignant behaviour of GC cells. Further mechanistic studies identified the NF-κB signaling pathway as a key downstream target of ADAMTS7, with ADAMTS7 silencing resulting in a notable reduction in NF-κB pathway activity. These findings establish ADAMTS7 as a significant contributor to the aggressiveness of GC and a pivotal activator of the NF-κB pathway, a major regulator of inflammation and tumor progression. Consequently, ADAMTS7 emerges as a promising therapeutic target and prognostic biomarker for GC. Our study opens new avenues for the development of targeted therapies aimed at inhibiting ADAMTS7 activity, thereby potentially improving treatment outcomes and survival rates for patients with GC.
BibTeX
@article{chen2024adamts,
  author = {Shun Chen and Jiancheng He and Hanxu Gao and Xian Gao and Lingchen Dai and Junjie Chen and Zhenyu Sha},
  title = {{ADAMTS7 Enhances Gastric Cancer Growth and Metastasis by Triggering the NF-κB Signaling Pathway}},
  journal = {Journal of Cancer},
  year = {2024},
  doi = {10.7150/jca.103093},
}
Figure